Non-Cochrane · prognostic · PM42278439
Prognostic Impact of miR-34a in Head and Neck Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.
Dioguardi Mario, Cantore Stefania, Guerra Ciro, et al. · International journal of molecular sciences · 2026 · PubMed · doi:10.3390/ijms27114909
Findings
Population Adults with head and neck squamous cell carcinoma (OSCC, LSCC, OPSCC, sinonasal SCC)
7 findings
| Low tumor tissue miR-34a expression | High tumor tissue miR-34a expression | Recurrence-free survival (RFS) Tumor tissue biomarker, prognostic studies | No data were available for recurrence-free survival No studies found 0 studies |
| Low tumor tissue miR-34a expression | High tumor tissue miR-34a expression | Cancer-specific survival (CSS) Tumor tissue biomarker, prognostic studies | No data were available for cancer-specific survival (the only cohort reporting CSS had no events in the high-expression group, so no hazard ratio was estimable) No studies found 0 studies |
| Low tumor-tissue miR-34a expression (study-defined cut-off) | High tumor-tissue miR-34a expression | Disease-free survival Tumor tissue biomarker prognostic studies · Random-effects model | HR 0.19 [0.00, 129.34] Very low Downgraded: risk of bias, imprecision, inconsistency 2 studies · 93 participants |
| Low tumor-tissue miR-34a expression (study-defined cut-off) | High tumor-tissue miR-34a expression | Overall survival Tumor tissue biomarker prognostic studies · Fixed-effects model | HR 2.25 [1.48, 3.41] Low Downgraded: risk of bias, inconsistency, publication bias 2 studies · 225 participants |
| Low tumor-tissue miR-34a expression (study-defined cut-off) | High tumor-tissue miR-34a expression | Disease-free survival Tumor tissue biomarker prognostic studies · Fixed-effects model | HR 2.92 [1.24, 6.88] Very low Downgraded: risk of bias, imprecision, inconsistency 2 studies · 93 participants |
| Low tumor-tissue miR-34a expression (study-defined cut-off) | High tumor-tissue miR-34a expression | Overall survival Tumor tissue biomarker prognostic studies · Random-effects model | HR 1.32 [0.32, 5.54] Low Downgraded: risk of bias, inconsistency, publication bias 2 studies · 225 participants |
| Low tumor tissue miR-34a expression | High tumor tissue miR-34a expression | Progression-free survival (PFS) Tumor tissue biomarker, prognostic studies | No data were available for progression-free survival No studies found 0 studies |
Included primary studies 4
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Ogawa 2012 miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. PMID:22624980 | 2012 | this review only | Disease-free survival | not extracted yet |
| Piotrowski 2021 miRNAs as Biomarkers for Diagnosing and Predicting Survival of Head and Neck Squamous Cell Carcinoma Patients. PMID:34439138 | 2021 | this review only | Overall survival | not extracted yet |
| Ren 2023 circFANCA accelerates the malignant process of OSCC by modulating miR-34a/PA28γ signaling. PMID:37148744 | 2023 | this review only | Overall survival | not extracted yet |
| Shen 2012 MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by targeting the antiapoptotic gene survivin. PMID:22246523 | 2012 | this review only | Disease-free survival | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Adults with HNSCC (OSCC, LSCC, HSCC, OPSCC, NPC) | HNSCC patients, 318 (183 OSCC, 102 LSCC, 24 sinonasal SCC, 9 OPSCC) (n=4 studies) |
| Intervention | Altered (low) miR-34a tumor tissue expression using study-defined cut-offs | Low tumor miR-34a expression |
| Comparison | Opposite expression category (high miR-34a) | High tumor miR-34a expression |
| Outcomes | OS (primary); PFS; RFS; DFS; CSS as HR, RR or Kaplan-Meier analyses | OS (n=2 studies, 4 cohorts, 225 patients); DFS (n=2 studies, 93 patients); no RFS, PFS or CSS data |
| Study designs | Primary studies of any design (randomized, non-randomized, prospective or retrospective cohort or case-control) | Retrospective studies (n=4) |
| Timing | Not specified | Follow-up about 50 to 150 months; unweighted mean 66 months |